Cargando…

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model

Pancreatic ductal adenocarcinoma(PDAC) does not respond to single-agent immune checkpoint inhibitor therapy, including anti-PD-1 antibody(aPD-1) therapy. Higher plasma levels of IL-8 are associated with poorer outcomes in patients who receive aPD-1 therapies, providing a rationale for combination im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Pan, Rozich, Noah, Wang, Jianxin, Wang, Junke, Xu, Yao, Herbst, Brian, Yu, Raymond, Muth, Stephen, Niu, Nan, Li, Keyu, Funes, Vanessa, Gai, Jessica, Osipov, Arsen, Edil, Barish H., Wolfgang, Christopher L., Lei, Ming, Liang, Tingbo, Zheng, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485862/ https://www.ncbi.nlm.nih.gov/pubmed/35533951 http://dx.doi.org/10.1016/j.canlet.2022.215722

Ejemplares similares

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
por: Kim, Victoria M., et al.
Publicado: (2019)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2020)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2022)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma
por: Wang, Jianxin, et al.
Publicado: (2022)

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody
por: Shiba, Michiru, et al.
Publicado: (2018)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
por: Sone, Kenbun, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
por: Wang, Yue, et al.
Publicado: (2023)

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer
por: Saung, May Tun, et al.
Publicado: (2018)

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity
por: Prendergast, Jillian M., et al.
Publicado: (2017)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
por: Jiang, Baijia, et al.
Publicado: (2017)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
por: Yoshida, Kazushige, et al.
Publicado: (2020)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
por: Zhang, Lin, et al.
Publicado: (2022)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Development of anti-feline PD-1 antibody and its functional analysis
por: Nishibori, Shoma, et al.
Publicado: (2023)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Anti-Hu antibodies activate enteric and sensory neurons
por: Li, Qin, et al.
Publicado: (2016)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

Association of anti‐gangliosides antibodies and anti‐CMV antibodies in Guillain–Barré syndrome
por: Wang, Lijuan, et al.
Publicado: (2017)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review
por: Shen, Tian, et al.
Publicado: (2020)

Presence of anti-nuclear antibody associated with worse clinical outcomes of anti-NMDAR encephalitis
por: Lei, Chunyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_enim4gljbau6luj83thcruv8eq